A study to evaluate treatment patterns and investigate adult patients with B-cell lymphoma - Clarity-BR

Study identifier:D8227R00003

ClinicalTrials.gov identifier:NCT07882576

EudraCT identifier:N/A

CTIS identifier:N/A

Will Be Recruiting

Official Title

WW-CLARITY: Real-world Characteristics, Treatments, and Outcomes of Treatment-Naïve (TN) Patients with Diffuse Large B- Cell Lymphoma (DLBCL) in the UK, France, Canada, and Brazil

Medical condition

Lymphoma, B-Cell

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

532

Study type

Observational

Age

18 Years - n/a

Date

Study Start Date: 30 Nov 2026
Estimated Primary Completion Date: 30 Jan 2027
Estimated Study Completion Date: 30 Jan 2027

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Oct 2026 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria